Tagged with Pharma

Colombia Rocío Mendez, country manager at bioMérieux Colombia, speaks about the many talents that make up the Colombian affiliate and explains how the company brings life-saving and innovative solutions to a thriving Colombian healthcare sector. This is your first time as a country manager. Why did the global management board think…

Austria Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia, willing volunteers and educated medical personnel balanced against a backdrop of economic stability. “Austria should be proud of the abundance…

Bulgaria Prof. Ilko Getov, PhD, MSc Pharm, MHM, president of the Bulgarian Pharmaceutical Union (BPhU) provides a fascinating insight into the changes sweeping across the pharmaceutical industry in Bulgaria and reveals the country’s determination to modernize its offerings in line with the highest in Europe. Could you please introduce yourself to…

Brazil Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over the past few years as well as his vision to propel the development of pharmaceutical sciences in the country. What…

Colombia Guillermo Browne, General Manager at MSD Colombia, reveals the strategic importance of the Colombian affiliate, hosting a global data management centre and regional pharmacovigilance operations, while highlighting the company’s commitment to continue advancing the therapeutic value of care and the clinical research landscape in Colombia. With 70 years of presence…

Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.  Could you introduce our readers to the…

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Bulgaria Deyan Denev, Executive Director of the Association of the Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares a clear overview of the role of innovative pharmaceutical players within Bulgaria, and the association’s commitment to working with government to enlarge patients’ access to innovative medicines. How has the overall situation for innovative…

Austria Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa from Alcon has assisted them in growing rapidly. Furthermore, he provides an insight into the importance of long-term strategic thinking,…

Colombia Antonio Cordova, general manager of seca Latin America, shares the story of the recent establishment of the affiliate in Colombia that serves as a regional center for operations within Latin America. You were appointed general manager for Latin America a year and half ago; what was your assigned mission when…

Austria Karl Peter Schwarz, general manager of the Austrian affiliate of LEO Pharma, an ambitious Danish company leading the way in innovative dermatology treatments, provides an in-depth look into how global partnerships and acquisitions have impacted the strategies and operations of the Austrian affiliate. Equally, he provides an insight into how…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…